Biotech · Private company
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Track this companyFree. Adds Medivation LLC, a wholly owned subsidiary of Pfizer Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials171 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials17
- A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active SurveillancePHASE2 · COMPLETED · started Jun 9, 2016ClinicalTrials.gov NCT02799745 · fetched Nov 12, 2026
- A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)PHASE3 · COMPLETED · started Mar 9, 2016ClinicalTrials.gov NCT02677896 · fetched Nov 12, 2026
- A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)PHASE2 · COMPLETED · started Nov 30, 2015ClinicalTrials.gov NCT02384382 · fetched Nov 12, 2026
- Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 17, 2014ClinicalTrials.gov NCT02319837 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast CancerPHASE2 · COMPLETED · started Sep 5, 2014ClinicalTrials.gov NCT02091960 · fetched Nov 12, 2026
- Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerPHASE3 · COMPLETED · started Oct 31, 2013ClinicalTrials.gov NCT02003924 · fetched Nov 12, 2026
- Safety Study of Continued Enzalutamide Treatment In Prostate Cancer PatientsPHASE4 · COMPLETED · started Oct 22, 2013ClinicalTrials.gov NCT01995513 · fetched Nov 12, 2026
- A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With EnzalutamidePHASE4 · COMPLETED · started Sep 25, 2013ClinicalTrials.gov NCT01977651 · fetched Nov 12, 2026
- Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerPHASE2 · COMPLETED · started Jun 12, 2013ClinicalTrials.gov NCT01889238 · fetched Nov 12, 2026
- Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate CancerPHASE2 · COMPLETED · started Aug 1, 2012ClinicalTrials.gov NCT01664923 · fetched Nov 12, 2026
- A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsPHASE2 · COMPLETED · started Jul 9, 2012ClinicalTrials.gov NCT01650194 · fetched Nov 12, 2026
- Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast CancerPHASE1 · COMPLETED · started Apr 30, 2012ClinicalTrials.gov NCT01597193 · fetched Nov 12, 2026
- Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate CancerPHASE1 · COMPLETED · started Jan 24, 2012ClinicalTrials.gov NCT01565928 · fetched Nov 12, 2026
- A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100PHASE2 · COMPLETED · started Oct 21, 2011ClinicalTrials.gov NCT01534052 · fetched Nov 12, 2026
- A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate CancerPHASE2 · COMPLETED · started Mar 22, 2011ClinicalTrials.gov NCT01288911 · fetched Nov 12, 2026
- A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate CancerPHASE3 · COMPLETED · started Sep 16, 2010ClinicalTrials.gov NCT01212991 · fetched Nov 12, 2026
- A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate CancerPHASE1 · COMPLETED · started Jul 23, 2007ClinicalTrials.gov NCT00510718 · fetched Nov 12, 2026